Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
NCT04533737 · LEO Pharma · PHASE4 · terminated · last registry update 2025-03-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The recruitment was terminated early due to delays and slow recruitment that significantly jeopardized the trial timelines. There were no safety concerns related to the early termination of the trial.” | – | Registry record, LEO Pharma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL17RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision